INT1060

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1976
Last Reported 2010
Negated 1
Speculated 1
Reported most in Abstract
Documents 50
Total Number 51
Disease Relevance 22.91
Pain Relevance 18.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (Pla2g1b) extracellular space (Pla2g1b) extracellular region (Pla2g1b)
response to stress (Pla2g1b)
Anatomy Link Frequency
platelet 3
polymorphonuclear leukocytes 3
nerve 1
Pla2g1b (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 173 100.00 Very High Very High Very High
agonist 21 100.00 Very High Very High Very High
corticosteroid 15 99.84 Very High Very High Very High
diclofenac 203 99.80 Very High Very High Very High
metalloproteinase 18 99.80 Very High Very High Very High
cINOD 32 99.78 Very High Very High Very High
antagonist 12 99.70 Very High Very High Very High
Chronic pancreatitis 8 99.56 Very High Very High Very High
Pain 22 99.50 Very High Very High Very High
Inflammatory response 11 99.46 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 210 100.00 Very High Very High Very High
Pancreatitis 98 99.84 Very High Very High Very High
Pressure And Volume Under Development 68 99.84 Very High Very High Very High
Sickle Cell Anemia 16 99.84 Very High Very High Very High
Pain 11 99.50 Very High Very High Very High
Opiate Addiction 18 98.88 Very High Very High Very High
Arthritis 7 98.60 Very High Very High Very High
Necrosis 5 98.24 Very High Very High Very High
Adhesions 21 98.04 Very High Very High Very High
Cancer 258 97.88 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This correlates with their potencies in blocking nerve conduction and inhibiting phospholipase A2.
Negative_regulation (inhibiting) of phospholipase A2 in nerve
1) Confidence 0.57 Published 1976 Journal J. Lipid Res. Section Abstract Doc Link 133194 Disease Relevance 0 Pain Relevance 0.34
SUMMARY OF BACKGROUND DATA: The anti-inflammatory mechanism of corticosteroids is considered to be caused by the inhibition of phospholipase A2, which plays an important role in the pain mechanism of lumbar disc problems.
Negative_regulation (inhibition) of phospholipase A2
2) Confidence 0.57 Published 2002 Journal Spine Section Body Doc Link 11840097 Disease Relevance 0 Pain Relevance 0
The fraction also showed weak inhibition of phospholipase A2 (PLA2) in-vitro.
Negative_regulation (inhibition) of phospholipase A2
3) Confidence 0.57 Published 1997 Journal J. Pharm. Pharmacol. Section Abstract Doc Link 9231356 Disease Relevance 0.62 Pain Relevance 0.23
Mepacrine, an inhibitor of phospholipase A2 (PLA2) activity and hence of arachidonic acid (AA) formation from membrane phospholipids, markedly inhibits (IC50 of approximately 15 microM) the release of VIP evoked by 4-AP.
Negative_regulation (inhibitor) of phospholipase A2
4) Confidence 0.44 Published 1989 Journal J. Neurosci. Section Abstract Doc Link 2545840 Disease Relevance 0 Pain Relevance 0.43
Responses induced by NMDA, carbachol or both agonists on microdiscs were reduced by phospholipase A2 inhibitors, the most striking effects being observed with mepacrine.
Negative_regulation (inhibitors) of phospholipase A2 associated with agonist
5) Confidence 0.41 Published 1999 Journal Eur. J. Neurosci. Section Abstract Doc Link 10103124 Disease Relevance 0 Pain Relevance 0.42
Pretreatment of mice with the phospholipase A2 (PLA2) inhibitors chlorpromazine or diltiazem one hour prior to APAP administration inhibits loss of mitochondrial Ca2+ homeostasis, prevents nuclear damage, and inhibits APAP hepatotoxicity as indicated by serum alanine aminotransferase activity and electron microscopic studies.
Negative_regulation (inhibitors) of phospholipase A2 associated with paracetamol and hepatotoxicity
6) Confidence 0.39 Published 1993 Journal Res. Commun. Chem. Pathol. Pharmacol. Section Abstract Doc Link 8434130 Disease Relevance 0.17 Pain Relevance 0.99
The marine natural produce manoalide has been reported to inactivate venom phospholipase A2 from several sources and phospholipase A2 from polymorphonuclear leukocytes.
Negative_regulation (inactivate) of phospholipase A2 in polymorphonuclear leukocytes
7) Confidence 0.37 Published 1988 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 3150849 Disease Relevance 0 Pain Relevance 0
The marine natural produce manoalide has been reported to inactivate venom phospholipase A2 from several sources and phospholipase A2 from polymorphonuclear leukocytes.
Negative_regulation (inactivate) of phospholipase A2 in polymorphonuclear leukocytes
8) Confidence 0.37 Published 1988 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 3150849 Disease Relevance 0 Pain Relevance 0
Inhibitors of phospholipase A2 and cyclooxygenase activity attenuated the positive inotropic effect of the agonists without modifying the negative chronotropic effect.
Negative_regulation (Inhibitors) of phospholipase A2 associated with agonist
9) Confidence 0.37 Published 1988 Journal Methods Find Exp Clin Pharmacol Section Abstract Doc Link 3135457 Disease Relevance 0 Pain Relevance 0.30
Indomethacin proved the most potent of the tested agents in inhibiting phospholipase-A2 activity in serum from patients with acute pancreatitis and should be further studied in vivo.
Negative_regulation (inhibiting) of phospholipase-A2 associated with pancreatitis
10) Confidence 0.37 Published 1997 Journal Scand. J. Clin. Lab. Invest. Section Abstract Doc Link 9279965 Disease Relevance 0.28 Pain Relevance 0.23
The inhibition of phospholipase-A2 was studied in vitro using 17 pharmacological agents in the search for a specific therapy for acute pancreatitis.
Negative_regulation (inhibition) of phospholipase-A2 associated with pancreatitis
11) Confidence 0.37 Published 1997 Journal Scand. J. Clin. Lab. Invest. Section Abstract Doc Link 9279965 Disease Relevance 0.42 Pain Relevance 0.07
Diclofenac (3.1 x 10(-2) mol l-1) reduced the phospholipase-A2 activity by 93%, ketoprofen (2.0 x 10(-2) mol l-1) or chlorpromazine (1.4 x 10(-2) mol l-1) by 90%, tobramycin (1.7 x 10(-2) mol l-1) by 84%, doxycycline (9.0 x 10(-3) mol l-1) by 61%, dexamethasone (1.7 x 10(-3) mol l-1) by 62%, methylprednisolone (3.8 x 10(-2) mol l-1) by 50%, and pindolol (1.0 x 10(-4) mol l-1) by 59%.
Negative_regulation (reduced) of phospholipase-A2 associated with dexamethasone and diclofenac
12) Confidence 0.37 Published 1997 Journal Scand. J. Clin. Lab. Invest. Section Abstract Doc Link 9279965 Disease Relevance 0.36 Pain Relevance 0.24
A weak inhibition of phospholipase-A2 activity was demonstrated by betamethasone, bupivacaine, digoxin, hydrocortisone, lidocaine, metoprolol, propranolol, and vancomycin.
Negative_regulation (inhibition) of phospholipase-A2 associated with lidocaine
13) Confidence 0.37 Published 1997 Journal Scand. J. Clin. Lab. Invest. Section Abstract Doc Link 9279965 Disease Relevance 0.26 Pain Relevance 0.25
Among all agents tested, anti-inflammatory drugs inhibited enzyme activity most significantly: indomethacin (9.0 x 10(-3) mol l-1) decreased the phospholipase-A2 activity to one- tenth.
Negative_regulation (decreased) of phospholipase-A2 associated with inflammation and cinod
14) Confidence 0.37 Published 1997 Journal Scand. J. Clin. Lab. Invest. Section Abstract Doc Link 9279965 Disease Relevance 0.43 Pain Relevance 0.16
[Manoalide: a new phospholipase A2 inhibitor of marine origin with potential immunoregulatory effect].
Negative_regulation (inhibitor) of phospholipase A2
15) Confidence 0.34 Published 1989 Journal Medicina (B Aires) Section Title Doc Link 2640487 Disease Relevance 0.22 Pain Relevance 0.24
Furthermore, several natural biflavonoids including ochnaflavone and ginkgetin inhibit phospholipase A2.
Negative_regulation (inhibit) of phospholipase A2
16) Confidence 0.34 Published 2008 Journal Arch. Pharm. Res. Section Abstract Doc Link 18409037 Disease Relevance 0.35 Pain Relevance 0.24
These molecules also exhibit phospholipase A2 and cyclooxygenase-2 inhibitory activity.
Negative_regulation (exhibit) of phospholipase A2
17) Confidence 0.34 Published 2008 Journal Arch. Pharm. Res. Section Abstract Doc Link 18409037 Disease Relevance 0.35 Pain Relevance 0.27
Comparison of nitric oxide synthase inhibitors, phospholipase A2 inhibitor and free radical scavengers as attenuators of opioid withdrawal syndrome.
Negative_regulation (inhibitor) of phospholipase A2 associated with narcan, withdrawal and opioid
18) Confidence 0.32 Published 2007 Journal Behav Pharmacol Section Title Doc Link 17989510 Disease Relevance 0.63 Pain Relevance 1.29
Furthermore, mepacrine (a phospholipase A2 inhibitor) significantly attenuated the morphine-induced withdrawal syndrome in a manner that was different than that with a NOS inhibitor.
Negative_regulation (inhibitor) of phospholipase A2 associated with withdrawal and morphine
19) Confidence 0.32 Published 2007 Journal Behav Pharmacol Section Abstract Doc Link 17989510 Disease Relevance 0.82 Pain Relevance 1.47
Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro.
Negative_regulation (Inhibition) of phospholipase-A2 associated with pancreatitis
20) Confidence 0.32 Published 1997 Journal Scand. J. Clin. Lab. Invest. Section Title Doc Link 9279965 Disease Relevance 0.44 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox